171 related articles for article (PubMed ID: 36030414)
1. Assessment of semaphorin 3A and semaphorin 7A levels in primary Sjogren's syndrome.
Urhan E; Urhan AC; Dogan HO; Sahin A
Rheumatol Int; 2023 Jun; 43(6):1087-1092. PubMed ID: 36030414
[TBL] [Abstract][Full Text] [Related]
2. Decreased Expression of Semaphorin 3A and Semaphorin 7A Levels and Its Association with Systemic Lupus Erythematosus.
Wang P; Mao YM; Liu LN; Zhao CN; Li XM; Pan HF
Immunol Invest; 2020 Feb; 49(1-2):69-80. PubMed ID: 31412748
[TBL] [Abstract][Full Text] [Related]
3. Semaphorin-3A,
Liu LN; Wang P; Zou YF; Xu Z; Cheng J; Zhang Y; Hu W; Pan HF
Autoimmunity; 2019 Jun; 52(4):161-167. PubMed ID: 31394943
[No Abstract] [Full Text] [Related]
4. [Association of Semaphorin 3A with thrombocytopenia in systemic lupus erythematosus].
Guo Q; Ma XX; Gao H; Shi LJ; Zhong YC; Xie LF; Shao M; Zhang XW
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Oct; 52(5):892-896. PubMed ID: 33047725
[TBL] [Abstract][Full Text] [Related]
5. Gene expression of semaphorin-3A, semaphorin-7A, neuropilin-1, plexin-C1, and β1 integrin in treated-multiple sclerosis patients.
Shapoori S; Mosayebi G; Ebrahimi Monfared M; Ghazavi A; Khansarinejad B; Farahani I; Ganji A
Neurol Res; 2020 Sep; 42(9):783-788. PubMed ID: 32497464
[TBL] [Abstract][Full Text] [Related]
6. Expression of semaphorin 3A, semaphorin 7A and their receptors in multiple sclerosis lesions.
Costa C; Martínez-Sáez E; Gutiérrez-Franco A; Eixarch H; Castro Z; Ortega-Aznar A; Ramón Y Cajal S; Montalban X; Espejo C
Mult Scler; 2015 Nov; 21(13):1632-43. PubMed ID: 26432853
[TBL] [Abstract][Full Text] [Related]
7. Association of Immune Semaphorins with COVID-19 Severity and Outcomes.
Vargovic M; Papic N; Samadan L; Balen Topic M; Vince A
Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893159
[TBL] [Abstract][Full Text] [Related]
8. Comparison of performance of the 2016 ACR-EULAR classification criteria for primary Sjögren's syndrome with other sets of criteria in Japanese patients.
Tsuboi H; Hagiwara S; Asashima H; Takahashi H; Hirota T; Noma H; Umehara H; Kawakami A; Nakamura H; Sano H; Tsubota K; Ogawa Y; Takamura E; Saito I; Inoue H; Nakamura S; Moriyama M; Takeuchi T; Tanaka Y; Hirata S; Mimori T; Matsumoto I; Sumida T
Ann Rheum Dis; 2017 Dec; 76(12):1980-1985. PubMed ID: 28330998
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of sema3A and sema7A in a murine model of multiple sclerosis: Implications for a therapeutic design.
Gutiérrez-Franco A; Costa C; Eixarch H; Castillo M; Medina-Rodríguez EM; Bribián A; de Castro F; Montalban X; Espejo C
Clin Immunol; 2016 Feb; 163():22-33. PubMed ID: 26686462
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of the 2016 ACR-EULAR and the 2002 AECG classification criteria for Sjögren's syndrome: Findings from the NIH cohort.
Billings M; Amin Hadavand M; Alevizos I
Oral Dis; 2018 Mar; 24(1-2):184-190. PubMed ID: 29480635
[TBL] [Abstract][Full Text] [Related]
11. The possible involvement of sema3A and sema4A in the pathogenesis of multiple sclerosis.
Eiza N; Garty M; Staun-Ram E; Miller A; Vadasz Z
Clin Immunol; 2022 May; 238():109017. PubMed ID: 35460904
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of serum semaphorin 3A and interleukin 6 levels in patients with pseudoexfoliation syndrome.
Okutucu M; Arpa M
Int Ophthalmol; 2023 Jun; 43(6):1995-2002. PubMed ID: 36445548
[TBL] [Abstract][Full Text] [Related]
13. Performance of the 2016 ACR/EULAR SS classification criteria in patients with secondary Sjögren's syndrome.
Hernández-Molina G; Ávila-Casado C; Hernández-Hernández C; Recillas-Gispert C; Sánchez-Guerrero J
Clin Exp Rheumatol; 2020; 38 Suppl 126(4):130-133. PubMed ID: 31994479
[TBL] [Abstract][Full Text] [Related]
14. Semaphorin 3A levels in vascular and nonvascular phenotypes in systemic sclerosis.
Kayaalp M; Erden A; Apaydin H; Güven SC; Armağan B; Cağlayan Kayaalp M; Andac Uzdogan E; Ala Enli Ş; Omma A; Kucuksahin O
Lab Med; 2023 Nov; 54(6):646-651. PubMed ID: 37100766
[TBL] [Abstract][Full Text] [Related]
15. Low Urine Secretion of Semaphorin3A in Lupus Patients with Proteinuria.
Doron R; Merav L; Nasrin E; Adi SD; Elias T; Gleb S; Itzhak R; Michael R; Zahava V
Inflammation; 2022 Apr; 45(2):603-609. PubMed ID: 34562225
[TBL] [Abstract][Full Text] [Related]
16. Expression of semaphorin class 3 is higher in the proliferative phase on the human endometrium.
Ferreira GD; Capp E; Jauckus J; Strowitzki T; Germeyer A
Arch Gynecol Obstet; 2018 May; 297(5):1175-1179. PubMed ID: 29450692
[TBL] [Abstract][Full Text] [Related]
17. Semaphorin 7A as a potential immune regulator and promising therapeutic target in rheumatoid arthritis.
Xie J; Wang H
Arthritis Res Ther; 2017 Jan; 19(1):10. PubMed ID: 28109308
[TBL] [Abstract][Full Text] [Related]
18. The involvement of semaphorin 7A in tumorigenic and immunoinflammatory regulation.
Song Y; Wang L; Zhang L; Huang D
J Cell Physiol; 2021 Sep; 236(9):6235-6248. PubMed ID: 33611799
[TBL] [Abstract][Full Text] [Related]
19. Semaphorins 3A and 7A: potential immune and neuroregenerative targets in multiple sclerosis.
Eixarch H; Gutiérrez-Franco A; Montalban X; Espejo C
Trends Mol Med; 2013 Mar; 19(3):157-64. PubMed ID: 23419749
[TBL] [Abstract][Full Text] [Related]
20. SS-B/La antigen purification, and ELISA detection of anti-SS-B/La antibodies in sera from patients with inflammatory connective tissue diseases.
Hansen B; Larsen P; Manthorpe R
Allergy; 1988 Nov; 43(8):577-85. PubMed ID: 3264663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
